ProShare Advisors
ARLZ

ProShare Advisors’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

ProShare Advisors’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-37,651
Closed -$86K – 1819
2017
Q3 		$86K Buy
37,651
+3,853
+11% +$5.16K ﹤0.01% 1335
2017
Q2 		$46K Sell
33,798
-1,122
-3% -$1.62K ﹤0.01% 1420
2017
Q1 		$75K Sell
34,920
-8,304
-19% -$31.2K ﹤0.01% 1526
2016
Q4 		$191K Buy
+43,224
New +$205K ﹤0.01% 1610

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BMCM
Bryn Mawr Capital Management Philadelphia, Pennsylvania $2.06B AUM 19.82% 1-Year Est. Return

ProShare Advisors's ARLZ Position: Q4 2017 in Review

ProShare Advisors sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q4 2017, closing a stake of 37,651 shares — an estimated $86K sold.

ProShare Advisors first reported a position in ARLZ in Q4 2016 and held it in 4 quarters. The position peaked at $191K in Q4 2016. 63 funds tracked by Wall St. Rank hold ARLZ as of Q4 2017.

  • ProShare Advisors reported no remaining Aralez Pharmaceuticals Inc. position as of Q4 2017 after selling out during the quarter.
  • ProShare Advisors sold 37,651 Aralez Pharmaceuticals Inc. shares in Q4 2017, an estimated $86K.
  • ProShare Advisors first reported a position in Aralez Pharmaceuticals Inc. in Q4 2016 and held it in 4 quarters.
  • ProShare Advisors's Aralez Pharmaceuticals Inc. position peaked at $191K in Q4 2016.
  • 63 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q4 2017.

Based on ProShare Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.